NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Director Sells $160,634.76 in Stock

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Director Mijia Wu sold 63,492 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $2.53, for a total value of $160,634.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of NYSEAMERICAN NBY opened at $2.14 on Thursday. NovaBay Pharmaceuticals, Inc. has a 52 week low of $0.23 and a 52 week high of $4.04.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.12). The firm had revenue of $1.49 million during the quarter.

A number of brokerages have recently commented on NBY. Zacks Investment Research raised NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating and set a $1.50 price objective on the stock in a report on Thursday, March 14th. Laidlaw lowered NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Finally, HC Wainwright lowered NovaBay Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $1.50 price objective on the stock. in a report on Wednesday, March 13th.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2019/06/13/novabay-pharmaceuticals-inc-nyseamericannby-director-sells-160634-76-in-stock.html.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Read More: Trading Penny Stocks

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply